PharmaEngine Prepares for Pancreatic Cancer Treatment Trial

PharmaEngine is preparing to launch a Phase II clinical trial using its PEP02 to treat patients with pancreatic cancer.

To begin next year in Taiwan and the U.S., the open-label trial will enroll patients with metastatic pancreatic cancer who have failed gemcitabine, a treatment used with chemotherapy.

The product is a liposome formulation of irinotecan. Irinotecan injection has been approved for the treatment of colorectal cancer and had sales of nearly $1 billion last year, the company said.